Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Olvimulogene nanivacirepvec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olvimulogene nanivacirepvec overview

Olvimulogene nanivacirepvec (GL-ONC1) is under development for the treatment of advanced peritoneal carcinomatosis, high grade epithelial carcinoma, endometrial cancer, ovarian cancer, advanced solid tumor, head and neck cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, melanoma, malignant pleural mesothelioma, fallopian tube cancer, hepatocellular carcinoma and malignant pleural effusion. The therapeutic candidate is administered through intravenous, intrapleural and intraperitoneal  infusion. GL-ONC1 is based on vaccinia virus which is genetically stable oncolytic virus lister strain designed to locate, enter, colonize and destroy cancer cells without harming healthy tissues or organs.

It was also under development for the treatment of acute myeloid leukemia.

Genelux overview

Genelux is a clinical stage biopharmaceutical company. It develops proprietary oncolytic virus based drugs and technologies. The company develops pipeline of products with applications for cancer detection and therapy. It conducts research and development activities in the field of oncolytic virotherapy. Genelux’s pipeline products include GL-ONC1, GL-ONC2, GL-ONC3, GL-ONC4, GL-CTC1, GL-IMG2 and V-VET-1. The company provides platform and imaging technologies such as targeted viruses armed for cancer therapy and companion diagnosis, customized viral vectors, highly specific deep tissue imaging, and veterinary oncology applications. It operates in San Diego and Redlands. Genelux is headquartered in San Diego, California, the US.

For a complete picture of Olvimulogene nanivacirepvec’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.